Blockade of reactive oxygen species and Akt activation is critical for anti-inflammation and growth inhibition of metformin in phosphatase and tensin homolog-deficient RAW264.7 cells

Immunopharmacology and Immunotoxicology

Volumn 35, Issue 6, 2013, Pages 669-677

  Lin, Chiou Feng ^a   Young, Kung Chia ^b   Bai, Chyi Huey ^c   Yu, Bu Chin ^b   Ma, Ching Ting ^a,d   Chien, Yu Chieh ^b,d   Su, Hui Chen ^e   Wang, Hue Yu ^e   Liao, Chao Sheng ^f   Lai, Hsin Wen ^f   Tsao, Chiung Wen ^d  

^a Institute of Clinical Medicine   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

^e CHI MEI MEDICAL CENTER   (Taiwan)

^f SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

Author keywords

COX 2 PGE2 production; INOS NO release; Metformin; Phosphatase and tensin homolog (PTEN); Reactive oxygen species

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BETA ACTIN; CYCLOOXYGENASE 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ACTIVATOR; INDUCIBLE NITRIC OXIDE SYNTHASE; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTAGLANDIN E2; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INACTIVATION; FLOW CYTOMETRY; MACROPHAGE; MEDIATOR RELEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; WESTERN BLOTTING;

ANIMALS; CELL LINE; CELL PROLIFERATION; ENZYME ACTIVATION; GENE KNOCKDOWN TECHNIQUES; HYPOGLYCEMIC AGENTS; INFLAMMATION; MACROPHAGES; METFORMIN; MICE; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; REACTIVE OXYGEN SPECIES;

EID: 84887896967     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923973.2013.837059     Document Type: Article

References (43)

1. Musi N, Goodyear LJ. AMP-activated protein kinase and muscle glucose uptake. Acta Physiol Scand 2003;178:337-345. (Pubitemid 36960424)
2. Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007;100:328-341.
3. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108: 1167-1174. (Pubitemid 32995375)
4. Pilon G, Dallaire P, Marette A. Inhibition of inducible nitric-oxide synthase by activators of AMP-activated protein kinase: A new mechanism of action of insulin-sensitizing drugs. J Biol Chem 2004;279:20767-20774. (Pubitemid 38656473)
5. Fisslthaler B, Fleming I. Activation and signaling by the AMPactivated protein kinase in endothelial cells. Circ Res 2009;105: 114-127.
6. Sag D, Carling D, Stout RD, Suttles J. Adenosine 50-monophosphate- activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J Immunol 2008; 181:8633-8641.
7. Drzewoski J, Drozdowska A, Sliwinska A. Do we have enough data to confirm the link between antidiabetic drug use and cancer development Pol Arch Med Wewn 2011;121:81-87.
8. Gonzalez-Angulo AM, Meric-Bernstam F. Metformin: A therapeutic opportunity in breast cancer. Clin Cancer Res 2010;16: 1695-1700.
9. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998;273:13375-13378. (Pubitemid 28268370)
10. Jiang BH, Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 2009;102:19-65.
11. Hyun T, Yam A, Pece S, et al. Loss of PTEN expression leading to high Akt activation in human multiple myelomas. Blood 2000;96: 3560-3568.
12. Stiles B, Wang Y, Stahl A, et al. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci USA 2004;101:2082-2087. (Pubitemid 38229018)
13. Slattery ML, Fitzpatrick FA. Convergence of hormones, inflammation, and energy-related factors: A novel pathway of cancer etiology. Cancer Prev Res 2009;2:922-930.
14. Slattery ML, Herrick JS, Lundgreen A, et al. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1. Carcinogenesis 2010;31:1604-1611.
15. Gupta SC, Hevia D, Patchva S, et al. Upsides and downsides of reactive oxygen species for cancer: The roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal 2012;16:1295-1322.
16. Kim SA, Choi HC. Metformin inhibits inflammatory response via AMPK-PTEN pathway in vascular smooth muscle cells. Biochem Biophys Res Commun 2012;7:866-872.
17. Huang X, Wullschleger S, Shpiro N, et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTENdeficient mice. Biochem J 2008;412:211-221. (Pubitemid 351758227)
18. Chang MY, Ho FM, Wang JS, et al. AICAR induces cyclooxygenase-2 expression through AMP-activated protein kinasetransforming growth factor-beta-activated kinase 1-p38 mitogenactivated protein kinase signaling pathway. Biochem Pharmacol 2010;80:1210-1220.
19. Jhun BS, Jin Q, Oh YT, et al. 5-Aminoimidazole-4-carboxamide riboside suppresses lipopolysaccharide-induced TNF-alpha production through inhibition of phosphatidylinositol 3-kinase/Akt activation in RAW 264.7 murine macrophages. Biochem Biophys Res Commun 2004;318:372-380. (Pubitemid 38553790)
20. Kim MJ, Park IJ, Yun H, et al. AMP-activated protein kinase antagonizes pro-apoptotic extracellular signal-regulated kinase activation by inducing dual-specificity protein phosphatases in response to glucose deprivation in HCT116 carcinoma. J Biol Chem 2010;285:14617-14627.
21. Liu H, Scholz C, Zang C, et al. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res 2012;32: 1627-1637.
22. Petti C, Vegetti C, Molla A, et al. AMPK activators inhibit the proliferation of human melanomas bearing the activated MAPK pathway. Melanoma Res 2012;22:341-350.
23. Sengupta TK, Leclerc GM, Hsieh-Kinser TT, et al. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: Implication for targeted therapy. Mol Cancer 2007;6:46.
24. Wu N, Gu C, Gu H, et al. Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153. Neoplasma 2011;58:482-490.
25. Trachootham D, Lu W, Ogasawara MA, et al. Redox regulation of cell survival. Antioxid Redox Signal 2008;10:1343-1374.
26. Ray PD, Huang BW, Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal 2012;24:981-990.
27. Leslie NR, Bennett D, Lindsay YE, et al. Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J 2003;22: 5501-5510. (Pubitemid 37279959)
28. Lee SR, Yang KS, Kwon J, et al. Reversible inactivation of the tumor suppressor PTEN by H2O2. J Biol Chem 2002;277: 20336-20342. (Pubitemid 34967328)
29. Sakamoto K, Iwasaki K, Sugiyama H, Tsuji Y. Role of the tumor suppressor PTEN in antioxidant responsive element-mediated transcription and associated histone modifications. Mol Biol Cell 2009;20:1606-1617.
30. De Luca A, Sanna F, Sallese M, et al. Methionine sulfoxide reductase A down-regulation in human breast cancer cells results in a more aggressive phenotype. Proc Natl Acad Sci USA 2010;107: 18628-18633.
31. Covey TM, Edes K, Coombs GS, et al. Alkylation of the tumor suppressor PTEN activates Akt and beta-catenin signaling: A mechanism linking inflammation and oxidative stress with cancer. PLoS One 2010;5:e13545.
32. Vinciguerra M, Foti M. PTEN at the crossroad of metabolic diseases and cancer in the liver. Ann Hepatol 2008;7:192-199.
33. Sedding DG, Widmer-Teske R, Mueller A, et al. Role of the phosphatase PTEN in early vascular remodeling. PLoS One 2013;8: e55445.
34. Labuzek K, Liber S, Gabryel B, Okopien B. Metformin has adenosine-monophosphate activated protein kinase (AMPK)-independent effects on LPS-stimulated rat primary microglial cultures. Pharmacol Rep 2010;62:827-848.
35. Waite KA, Eng C. Protean PTEN: form and function. Am J Hum Genet 2002;70:829-844. (Pubitemid 34259300)
36. Baba Y, Nosho K, Shima K, et al. Prognostic significance of AMPactivated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer. Br J Cancer 2010;103:1025-1033.
37. Adachi M, Brenner DA. High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase. Hepatology 2008;47:677-685. (Pubitemid 351280736)
38. Balkwill F, Mantovani A. Cancer and inflammation: Implications for pharmacology and therapeutics. Clin Pharmacol Ther 2010;87: 401-406.
39. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005;7:211-217. (Pubitemid 40568680)
40. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-444.
41. Furumoto Y, Brooks S, Olivera A, et al. Cutting edge: lentiviral short hairpin RNA silencing of PTEN in human mast cells reveals constitutive signals that promote cytokine secretion and cell survival. J Immunol 2006;176:5167-5171.
42. Anezaki Y, Ohshima S, Ishii H, et al. Sex difference in the liver of hepatocyte-specific Pten-deficient mice: A model of nonalcoholic steatohepatitis. Hepatol Res 2009;39:609-618.
43. Horie Y, Suzuki A, Kataoka E, et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 2004;113:1774-1783. (Pubitemid 39071669)